In the first analyses of this trial, 115 patients with mCRPC progression after one or two lines of an androgen receptor inhibitor (abiraterone or enzalutamide) or taxane-based therapy and harboring a germline or somatic BRCA1/2 mutation (as determined by germline testing, NGS of tumor tissue, or assay of circulating tumor DNA) received rucaparib 600 mg twice daily (orally) [97]. The gene discussed is BRCA1; the disease is neoplasm.